Company Overview and News

Your Daily Pharma Scoop: Reata Provides Update, Assembly Biosciences Data, Bellicum's BPX-501

2018-04-13 seekingalpha
Today we will discuss Reata Pharmaceuticals (RETA), which provided an update on the phase 2 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) due to Alport syndrome.
Upvote Downvote

Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome

2018-04-11 globenewswire
IRVING, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today provided an update on the ongoing Phase 2 CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) due to Alport syndrome. The Phase 2 portion of CARDINAL enrolled 30 patients to receive bardoxolone orally, once-daily for two years.
Upvote Downvote

Commerce Bancshares upgraded to market perform from underperform at Raymond James

2018-04-10 marketwatch
A new study suggests that losing a major part of your wealth may be as consequential for your health as never having it at all
Upvote Downvote

AnaptysBio downgraded to sector perform from outperform at RBC Capital

2018-04-04 marketwatch
3 Stocks to Watch on Tuesday: Aimmune Therapeutics Inc (AIMT), AnaptysBio Inc (ANAB) and SM Energy Co (SM)
Upvote Downvote

Reata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology Conference

2018-04-03 globenewswire
IRVING, Texas, April 03, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced the upcoming presentation of preclinical data for its novel RORγt inverse agonist RTA 1701 at the Annual Meeting of the American Association of Immunologists in Austin, Texas on May 6-7, 2018. RTA 1701 is the lead product candidate from Reata’s proprietary series of RORγt inverse agonists for the potential treatment of a broad range of autoimmune, inflammatory, and fibrotic diseases.
Upvote Downvote

Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan

2018-03-29 globenewswire
IRVING, Texas, March 29, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa Hakko Kirin Co. Ltd. (Kyowa Hakko Kirin), received designation under the Priority Review and Designation System, or SAKIGAKE Designation, by the Japanese Ministry of Health, Labour and Welfare, for bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease (DKD).
Upvote Downvote

U.S. Biotech/Pharma Sector Daily Observations Letter: March 22, 2018

2018-03-23 seekingalpha
We examine the possible reasons why Reata Pharmaceuticals (RETA) stock did not respond well to today's successful phase 2 data.
Upvote Downvote

Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial

2018-03-22 globenewswire
IRVING, Texas, March 22, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced positive top-line data from the Phase 2 LARIAT trial evaluating bardoxolone methyl (bardoxolone) for the treatment of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). After demonstrating clinically meaningful improvements in six-minute walk distance (6MWD) in patients with connective tissue disease associated PAH (CTD-PAH), the Company initiated small, exploratory studies in cohorts of pulmonary hypertension due to interstitial lung disease to identify potential expansion opportunities.
Upvote Downvote

Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference

2018-03-16 globenewswire
IRVING, Texas, March 16, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced that Chief Development Officer, Keith Ward, Ph.D., will present at the 15th Annual BIO Asia International Conference on Tuesday, March 20, 2018, at 8:30 a.m. JST in Tokyo, Japan. The BIO Asia conference is a premier partnering-focused event for the biopharmaceutical industry, and Reata’s selection as a presenting company highlights the strength of its early-stage assets, including RTA 901 and RTA 1701.
Upvote Downvote

Biotech Analysis Central Pharma News: Conatus Leaps On Upgrade, Reata Fails Mid-Stage Study, Synergy's Strategy Shift

2018-03-05 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
Upvote Downvote

RETA / Reata Pharmaceuticals, Inc. S-8 03/02/2018

reta-s8.htm As filed with the Securities and Exchange Commission on March 2, 2018
Upvote Downvote

RETA / Reata Pharmaceuticals, Inc. 10-K 2017 (Annual Report)

reta-10k_20171231.htm UNITED STATES
Upvote Downvote

BRIEF-Reata Provides Program Update On Phase 2 Rare Renal Clinical Trials

2018-02-27 reuters
* REATA PHARMACEUTICALS INC - FIRST DATA FROM PHOENIX EXPECTED 2H18 Source text for Eikon: Further company coverage:
Upvote Downvote

Reata Pharmaceuticals A Buy On Bardoxolene Data

2018-02-14 seekingalpha
Reata Pharmaceuticals (RETA) is a clinical-stage biotechnology company specializing in drugs that affect mitochondria-related diseases. Its lead candidate is for PAH (pulmonary arterial hypertension) resulting from connective tissue disease.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 75615P103